US › Healthcare

Moleculin Biotech Inc (MBRX)

US · Healthcare · Biotechnology

$0.28-24.32%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.6M

EPS

$-1.40

EPS estimate

$-1.55

EPS came in at -1.40 against a street estimate of -1.55 — a beat of 9.7%.

Key statistics

Market cap

$8.9M

P/E

0.0

Forward P/E

0.0

P/B

0.92

Book value

$1.63

EPS (TTM)

$8.98

52-week high

$15.75

52-week low

$0.16

50-day MA

$0.58

200-day MA

$2.25

Beta

2.00

Analyst view

Analysts rate Moleculin Biotech Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $12.00.

Shareholding

Insiders

6.13%

Institutions

8.19%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.23%
Vanguard Capital Management, LLC	0.21%
Vanguard Fiduciary Trust Co	0.15%
XTX Topco Ltd	0.11%
Morgan Stanley - Brokerage Accounts	0.10%
Rockefeller Capital Management L.P.	0.07%
Tower Research Capital LLC	0.02%
Citigroup Inc	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Moleculin Biotech Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.